Effects of levodopa on motor sequence learning in Parkinson's disease

Neurology

Volumn 60, Issue 11, 2003, Pages 1744-1749

  Feigin, A ^a,b,c   Ghilardi, M F ^d   Carbon, M ^a   Edwards, C ^a   Fukuda, M ^a,b,c   Dhawan, V ^a,b,c   Margouleff, C ^a,b,c   Ghez, C ^d   Eidelberg, D ^a,b,c  

^a N Shore Long Isl Jewish Res Inst ^*  (United States)

^b NORTH SHORE UNIVERSITY HOSPITAL   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Columbia Coll of Phys and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVODOPA; OXYGEN 15; WATER;

ADULT; AGED; ARTICLE; BEHAVIOR; BRAIN FUNCTION; BRAIN REGION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG INFUSION; FEMALE; HUMAN; LEARNING; MALE; MOTOR PERFORMANCE; OCCIPITAL CORTEX; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PREMOTOR CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RIGHT HANDEDNESS; TASK PERFORMANCE; TREATMENT OUTCOME;

EID: 0038579361     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.WNL.0000072263.03608.42     Document Type: Article

References (43)

1. Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug-induced hallucinations in parkinsonian patients. Neurology 1998;51:811-814.
2. Sacks OW, Kohl MS, Messeloff CR, Schwartz WF. Effects of levodopa in parkinsonian patients with dementia. Neurology 1972;22:516-519.
3. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983;106:257-270.
4. Brown RG, Marsden CD. Cognitive function in Parkinson's disease: from description to theory. Trends Neurosci 1990;13:21-29.
5. Mattay VS, Tessitore A, Callicott JH, et al. Dopaminergic modulation of cortical function in patients with Parkinson's disease. Ann Neurol 2002;51:156-164.
6. Kulisevsky J, Avila A, Barbanoj M, Antonijoan R, Berthier ML, Gironell A. Acute effects of levodopa on neuropsychological performance in stable and fluctuating Parkinson's disease patients at different levodopa plasma levels. Brain 1996;119:2121-2132.
7. Feigin A, Fukuda M, Dhawan V, et al. Metabolic correlates of levodopa response in Parkinson's disease. Neurology 2001;57:2083-2088.
8. Feigin A, Ghilardi MF, Fukuda M, et al. Effects of levodopa infusion on motor activation responses in Parkinson's disease. Neurology 2002;59:220-226.
9. Carbon M, Eidelberg D. Modulation of regional brain function by deep brain stimulation: studies with positron emission tomography. Curr Opin Neurol 2002;15:451-455.
10. Bowen FP, Kamienny RS, Burns MM, Yahr M. Parkinsonism: effects of levodopa treatment on concept formation. Neurology 1975;25:701-704.
11. Lange KW, Paul GM, Naumann M, Gsell W. Dopaminergic effects on cognitive performance in patients with Parkinson's disease. J Neural Transm [Suppl] 1995;46:423-432.
12. Lange KW, Robbins TW, Marsden CD, James M, Owen AM, Paul GM. L-Dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology 1992;107:394-404.
13. Gotham AM, Brown RG, Marsden CD. Levodopa treatment may benefit or impair "frontal" function in Parkinson's disease. Lancet 1986;2:970-971.
14. Gotham AM, Brown RG, Marsden CD. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain 1988;111:299-321.
15. Pillon B, Dubois B, Bonnet AM, et al. Cognitive slowing in Parkinson's disease fails to respond to levodopa treatment: the 15-objects test. Neurology 1989;39:762-768.
16. Mohr E, Fabbrini G, Ruggieri S, Fedio P, Chase TN. Cognitive concomitants of dopamine system stimulation in parkinsonian patients. J Neurol Neurosurg Psychiatry 1987;50:1192-1196.
17. Cooper JA, Sagar HJ, Doherty SM, Jordan N, Tidswell P, Sullivan EV. Different effects of dopaminergic and anticholinergic therapies on cognitive and motor function in Parkinson's disease. A follow-up study of untreated patients. Brain 1992;115:1701-1725.
18. Poewe W, Berger W, Benke T, Schelosky L. High-speed memory scanning in Parkinson's disease: adverse effects of levodopa. Ann Neurol 1991;29:670-673.
19. Rafal RD, Posner MI, Walker JA, Friedrich FJ. Cognition and the basal ganglia. Separating mental and motor components of performance in Parkinson's disease. Brain 1984;107:1083-1094.
20. Cools R, Stefanova E, Barker RA, Robbins TW, Owen AM. Dopaminergic modulation of high-level cognition in Parkinson's disease: the role of the prefrontal cortex revealed by PET. Brain 2002;125:584-594.
21. Ghilardi MF, Ghez CP, Moeller JR, Dhawan V, Eidelberg D. Patterns of regional brain activation associated with different aspects of motor learning. Brain Res 2000;871:127-145.
22. Nakamura T, Ghilardi MF, Mentis M, et al. Functional networks in motor sequence learning: abnormal topographies in Parkinson's disease. Hum Brain Map 2001;12:42-60.
23. Fukuda M, Ghilardi MF, Carbon M, et al. Pallidal stimulation for parkinsonism: improved brain activation during sequence learning. Ann Neurol 2002;52:144-152.
24. Ghilardi MF, Ghez CP, Feigin A, Hacking A, Fukuda M, Eidelberg D. Motor sequence learning in Parkinson's disease: differential effects of levodopa and DBS. Neurology 2001;56:A147.
25. Fukuda M, Mentis MJ, Ghilardi MF, et al. Functional correlates of pallidal stimulation for Parkinson's disease. Ann Neurol 2001;49:155-165.
26. Fahn S, Elton R. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden C, Calne D, Goldstein M, eds. Recent developments in Parkinson's disease. New York: Macmillan, 1987:293-304.
27. Ghez CP, Favilla M, Ghilardi MF, Gordon J, Bermejo R, Pullman S. Discrete and continuous planning of hand movements and isometric force trajectories. Exp Brain Res 1997;115:217-233.
28. Dhawan V, Kazumata K, Robeson W, et al. Quantitative brain PET: comparison of 2D and 3D acquisition on the GE Advance Scanner. Clin Pos Imag 1998;1:135-144.
29. 2(15)O regional cerebral blood flow three-dimensional imaging technique. J Cereb Blood Flow Metab 1993;13:617-629.
30. Saint-Cyr JA, Trepanier LL, Kumar R, Lozano AM, Lang AE. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain 2000;123:2091-2108.
31. Brusa L, Pierantozzi M, Peppe A, et al. Deep brain stimulation (DBS) attentional effects parallel those of L-dopa treatment. J Neural Transm 2001;108:1021-1027.
32. Sakai K, Hikosaka O, Takino R, Miyauchi S, Nielsen M, Tamada T. What and when: parallel and convergent processing in motor control. J Neurosci 2000;20:2691-2700.
33. Sakai K, Hikosaka O, Miyauchi S, Takino R, Sasaki Y, Putz B. Transition of brain activation from frontal to parietal areas in visuomotor sequence learning. J Neurosci 1998;18:1827-1840.
34. Grafton ST, Hazeltine E, Ivry R. Functional mapping of sequence learning in normal humans. J Cogn Neurosci 1995;7:497-510.
35. Honda M, Deiber M-P, Ibanez V, Pascual-Leone A, Zhuang P, Hallett M. Dynamic cortical involvement in implicit and explicit motor learning: a PET study. Brain 1998;121:2159-2173.
36. Kaasinen V, Nagren K, Hietala J, et al. Extrastriatal dopamine D2 and D3 receptors in early and advanced Parkinson's disease. Neurology 2000;54:1482-1487.
37. Rauch SL, Savage CR, Brown HD, et al. A PET investigation of implicit and explicit sequence learning. Hum Brain Map 1995;3:271-286.
38. Delforge J, Bottlaender M, Loc'h C, Dolle F, Syrota A. Parametric images of the extrastriatal D2 receptor density obtained using a high-affinity ligand (FLB 457) and a double-saturation method. J Cereb Blood Flow Metab 2001;21:1493-1503.
39. Porrino LJ, Burns RS, Crane AM, Palombo E, Kopin IJ, Sokoloff L. Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys. Proc Natl Acad Sci USA 1987;84:5995-5999.
40. Imamura T, Ishii K, Hirono N, et al. Visual hallucinations and regional cerebral metabolism in dementia with Lewy bodies (DLB). Neuroreport 1999;10:1903-1907.
41. Imamura T, Ishii K, Hirono N, et al. Occipital glucose metabolism in dementia with Lewy bodies with and without parkinsonism: a study using positron emission tomography. Dement Geriatr Cogn Disord 2001;12:194-197.
42. Fukuda M, Mentis MJ, Ma Y, et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting state glucose metabolism. Brain 2001;124:1601-1609.
43. Su P, Ma Y, Fukuda M, et al. Metabolic changes following subthalamotomy for advanced Parkinson's disease. Ann Neurol 2001;50:514-520.